173 related articles for article (PubMed ID: 18552208)
1. Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice.
Funk RK; Maxwell TJ; Izumi M; Edwin D; Kreisel F; Ley TJ; Cheverud JM; Graubert TA
Blood; 2008 Aug; 112(4):1434-42. PubMed ID: 18552208
[TBL] [Abstract][Full Text] [Related]
2. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia.
Le Beau MM; Bitts S; Davis EM; Kogan SC
Blood; 2002 Apr; 99(8):2985-91. PubMed ID: 11929790
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.
Knight JA; Skol AD; Shinde A; Hastings D; Walgren RA; Shao J; Tennant TR; Banerjee M; Allan JM; Le Beau MM; Larson RA; Graubert TA; Cox NJ; Onel K
Blood; 2009 May; 113(22):5575-82. PubMed ID: 19299336
[TBL] [Abstract][Full Text] [Related]
4. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
5. Integrated genomics of susceptibility to alkylator-induced leukemia in mice.
Cahan P; Graubert TA
BMC Genomics; 2010 Nov; 11():638. PubMed ID: 21080971
[TBL] [Abstract][Full Text] [Related]
6. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences.
Grisolano JL; Wesselschmidt RL; Pelicci PG; Ley TJ
Blood; 1997 Jan; 89(2):376-87. PubMed ID: 9002938
[TBL] [Abstract][Full Text] [Related]
7. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia.
Le Beau MM; Davis EM; Patel B; Phan VT; Sohal J; Kogan SC
Blood; 2003 Aug; 102(3):1072-4. PubMed ID: 12689927
[TBL] [Abstract][Full Text] [Related]
8. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice.
Fenske TS; McMahon C; Edwin D; Jarvis JC; Cheverud JM; Minn M; Mathews V; Bogue MA; Province MA; McLeod HL; Graubert TA
Cancer Res; 2006 May; 66(10):5029-38. PubMed ID: 16707424
[TBL] [Abstract][Full Text] [Related]
9. Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation.
Gaillard C; Tokuyasu TA; Rosen G; Sotzen J; Vitaliano-Prunier A; Roy R; Passegué E; de Thé H; Figueroa ME; Kogan SC
Haematologica; 2015 Aug; 100(8):1064-75. PubMed ID: 26088929
[TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia.
Lee GY; Christina S; Tien SL; Ghafar AB; Hwang W; Lim LC; Lim TH
Cancer Genet Cytogenet; 2005 Jun; 159(2):129-36. PubMed ID: 15899384
[TBL] [Abstract][Full Text] [Related]
11. Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia.
Gaillard C; Surianarayanan S; Bentley T; Warr MR; Fitch B; Geng H; Passegué E; de Thé H; Kogan SC
Blood Adv; 2018 Oct; 2(19):2462-2466. PubMed ID: 30266821
[TBL] [Abstract][Full Text] [Related]
12. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of alkylator-associated acute myeloid leukemia.
Knoche E; McLeod HL; Graubert TA
Pharmacogenomics; 2006 Jul; 7(5):719-29. PubMed ID: 16886897
[TBL] [Abstract][Full Text] [Related]
14. Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA.
Keeshan K; Vieugué P; Chaudhury S; Rishi L; Gaillard C; Liang L; Garcia E; Nakamura T; Omidvar N; Kogan SC
Haematologica; 2016 Oct; 101(10):1228-1236. PubMed ID: 27390356
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel TNRC18-RARA fusion in acute promyelocytic leukemia lacking t(15;17)(q24;q12)/PML-RARA.
Wang Z; Wen L; Zhang L; Xu X; Chen X; Yao L; Wang M; Shen Z; Mo G; Wang Y; Zhao D; Cai W; Shen J; Chi X; Xu Y; Zeng Z; Pan J; Ruan C; Wu D; Jia Z; Chen S
Mol Carcinog; 2021 Feb; 60(2):. PubMed ID: 33428799
[TBL] [Abstract][Full Text] [Related]
16. Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity.
Jonas BA; Johnson C; Gratzinger D; Majeti R
PLoS One; 2016; 11(7):e0159189. PubMed ID: 27428079
[TBL] [Abstract][Full Text] [Related]
17. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia.
Jones L; Wei G; Sevcikova S; Phan V; Jain S; Shieh A; Wong JC; Li M; Dubansky J; Maunakea ML; Ochoa R; Zhu G; Tennant TR; Shannon KM; Lowe SW; Le Beau MM; Kogan SC
J Exp Med; 2010 Nov; 207(12):2581-94. PubMed ID: 21059853
[TBL] [Abstract][Full Text] [Related]
18. A review of the mutagenic potential of N-ethyl-N-nitrosourea (ENU) to induce hematological malignancies.
Nath P; Maiti D
J Biochem Mol Toxicol; 2022 Jul; 36(7):e23067. PubMed ID: 35393684
[TBL] [Abstract][Full Text] [Related]
19. Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model.
Santana BA; Pintão MC; Abreu e Lima RS; Scheucher PS; Santos GA; Garcia AB; Falcão RP; Rego EM
Braz J Med Biol Res; 2006 May; 39(5):615-20. PubMed ID: 16648899
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
